-
Saudi Arabia is expanding its ambitions in advanced therapies through Vision 2030, focusing on building local biomanufacturing capabilities and accelerating access to cell and gene therapies.
-
This discussion examines how next‑gen platforms and predictive modelling approaches provide the process insight to drive consistency, yield, and potency as programs move towards commercialization.
-
Vitrafy solves the challenge of inconsistent, manual, and hard-to-scale cryopreservation processes that can compromise cell quality and therapy outcomes.
-
This session is designed for cell and gene therapy developers, process development teams, and manufacturing leaders seeking to accelerate timelines while reducing manufacturing costs.
-
US biotech companies expanding clinical trials into the EU and UK face complex regulatory and logistics challenges. Damian Larington shares key requirements, common mistakes and emerging trial trends.
-
BBG Advanced Therapies has built infrastructure to both help developers access reliable high-quality starting material, as well as downstream support for testing, manufacturing, and logistics.
-
Excellos specializes in deep characterization of starting materials for adaptive immunotherapies for the better cellular immunotherapies as well as being flexibility in novel process development.
-
Teknova leverages their modular manufacturing platform to help novel therapy developers across cell and gene therapy, mRNA, and next-generation antibodies accelerate their breakthroughs.
-
Symcel addresses one of the biggest remaining bottlenecks in cell & gene therapy: QC release, through a breakthrough rapid, growth-based microbial detection system.
-
What if accelerating innovation and reducing risk were not opposing forces? This session looks at how the trade-off can be overcome from a CMC perspective.
-
Hear how Marken is rising to constant global disruptions — embracing innovation, reducing risk, and building future-ready solutions that balance speed, cost, and control.
-
Life sciences companies are accelerating digital transformation while maintaining regulatory compliance. Assurea explains how AI, integrated quality systems and analytics are reshaping the industry.
-
One of the biggest hurdles sponsors face is finding a CDMO with true commercial AAV experience—partners who have successfully taken them through global approvals into the commercial market.
-
GeminiBio and Tolemy Bio will introduce aiMOS™, an AI-driven media optimization service that helps teams reduce variability, increase performance, and improve manufacturability.
-
Limula is addressing the challenges of clinical centres and biotech companies looking for a solution enabling fully automated production of cell therapies at the point-of-care.
-
As a cell therapy advances to commercial-scale manufacturing, success depends on strategic partnerships that ensure quality, consistency, and regulatory compliance while enabling scalability.
-
In a complex, volatile global market, manufacturability is no longer something to address “when the time comes”-it must be built into the therapy from day one
-
CaseBioscience focuses on preservation of cells for storage and transport, so cell therapy developers have a partner for this crucial aspect of the cell therapy workflow.
-
NKILT Therapeutics brings a novel off-the-shelf cell therapy to tackle over half of cancers across hematologic and solid tumors.
